SCHEMBL2642647

SCHEMBL2642647

N#Cc1cccc(F)c1S

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 4/20 0.47
BCAT1 P54687 1/20 0.39
TSHR P16473 1/20 0.38
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CUL4A Q13619 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MCL1 Q07820 1/20 0.33
HTR2A P28223 1/20 0.33
KAT6A Q92794 1/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
PGR P06401 1/20 0.33
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3058843 0.83 TSHR (0.46) TRPV4TSHRCA1CA2MCL1
SCHEMBL30443847 0.76 BCAT1 (0.49) TRPV4BCAT1TSHRCA1CA2
SCHEMBL158537 0.76 BCAT1 (0.49) TRPV4BCAT1TSHRCA1CA2
SCHEMBL1966377 0.76 TSHR (0.41) TRPV4TSHRCA1CA2MCL1
Water SCHEMBL28049227 0.76 BCAT1 (0.49) TRPV4BCAT1TSHRCA1CA2
SCHEMBL30489137 0.75
SCHEMBL30349228 0.75
SCHEMBL100446 0.75
Benzene SCHEMBL28603062 0.74 BCAT1 (0.47) TRPV4BCAT1TSHRCA1CA2
SCHEMBL186554 0.74 KDM4E (0.44) TRPV4BCAT1TSHRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9662328-B2 Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells NATIONAL TAIWAN UNIVERSITY (TW) 2017-05-30 US disclosed
US-20160151362-A1 TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS NATIONAL TAIWAN UNIVERSITY (TW) 2016-06-02 US disclosed
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
EP-1734040-A1 SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160151362-A1 TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS DTYMK, TYMP, TK1 TRPV4 4115/4885BCAT1 1503/4885TSHR 3702/4885
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK TRPV4 2840/4885BCAT1 1408/4885TSHR 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.